• To examine the time between regulatory approval and launch/pricing and reimbursement (P&R) approval (as defined in Table 1 ) in the EU5 and US -Illustrate any differences between general medicines, oncology and orphan drugs within and across the countries -Look for changes in these timelines over a 6 year period (January 2009 to December 2015)
• New molecular entities, formulations and combinations approved by the EMA (EC centralized approval) between January 2009 and December 2015 were included in the analysis. FDA approval dates were retrieved.
• Time comparison for general medicines vs. orphan and oncology indications was made including shifts over time
• Timing differences were NOT weighted by the number of products not available by country and category
OBJECTIVE AND METHODS
• Increasing divergence between regulatory and P&R approval and a dearth of literature on time to market access in recent times makes this topic both a relevant and interesting issue for analysis -~80% of all EMA approved medications in this time period were available in Germany, whereas only 45% had completed P&R negotiations in France § 72% of medications that had completed P&R in France were available across the EU5 and 83% were available in at least 3 of the other markets (in most cases the medication had not completed P&R in Spain but was available in Italy, Germany and the UK) -Spain has the poorest access for orphan drugs; only 28% of orphan medications approved by the EMA in this time period had completed P&R negotiations in Spain as of December 2015 German analysis includes 16 drugs that were withdrawn from the German market post launch either after G-BA assessment and/or reimbursement price negotiation with the GKV (Betmiga, Constella, Fycompa, Invokana, Latuda, Lojuxta, Lyxumia, Orphacol, Rasilamlo, Trajenta, Translarna, Tresiba, Trobalt, Vokanamet, Xiapex, Yellox were withdrawn as of May 2016) Spain 50%
Italy, 65%
France, 45%
Germany, 80%
UK, 73% 
